Table 1 Baseline disease and patient characteristics

From: Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

Characteristics, n (%)

Mucosal N = 84

Nonmucosal N = 1483

P-valuec

Age, median (range), years

64 (15–87)

61 (18–94)

0.4805

 ≥65 years

41 (49%)

620 (42%)

0.2061

Women

48 (57%)

568 (38%)

0.0006

ECOG PS 1

27 (32%)

513 (35%)

0.6459

Elevated LDH

40 (48%)

537 (36%)

0.0349

BRAFV600 mutant

7 (8%)

427 (29%)

<0.0001

M1c disease

68 (81%)

1102 (74%)

0.1732

Liver metastases

20 (24%)

286 (19%)

0.3089

Baseline tumour size ≥ 80.5 mma

49 (58%)

645 (43%)

0.0077

PD-L1 positiveb

46 (70%)

888 (77%)

0.1675

No. of prior systemic therapies

  0

8 (10%)

150 (10%)

0.0462

  1

31 (37%)

639 (43%)

─

  2

38 (45%)

467 (31%)

─

 ≥3

7 (8%)

227 (15%)

─

 Prior chemotherapy

18 (21%)

233 (16%)

0.1646

 Prior ipilimumab

33 (39%)

666 (45%)

0.3131

  1. ECOG eastern cooperative oncology group, LDH lactate dehydrogenase
  2. aBaseline tumour size is the sum of the longest diameters of target lesion. 80.5 mm is the median in the total population
  3. bPercentage is calculated using the number of patients with known PD-L1 status as the denominator (n = 66 for mucosal and 1152 for nonmucosal)
  4. cBased on t-test for age and on chi-square test for other characteristics
Back to article page